CPX-351 improves survival following allogeneic hematopoietic cell transplant in acute myeloid leukemia patients

December 5, 2016

Acute myeloid leukemia, or AML, is a type of cancer of the blood and bone marrow. It occurs most often in older populations and progresses rapidly, interfering with the production of red blood cells, white blood cells and platelets. Treatments include chemotherapy, drug therapy and stem-cell transplants.

A of a phase 3 trial shows that with high-risk or secondary AML, who received initial treatment with CPX-351, had improved survival following allogeneic hematopoietic cell transplant, when compared with patients who received standard 7+3 cytarabine and daunorubicin as initial therapy. Moffitt Cancer Center physician Jeffrey Lancet, M.D., will present the results at the American Society of Hematology Conference Annual Meeting in San Diego.

Cytarabine combined with daunorubicin (7+3) is commonly used to treat AML; however, older patients with AML usually respond poorly to this treatment regimen alone. Patients who are eligible and respond to initial treatment often have the option to receive allogeneic hematopoietic cell transplants.

CPX-351 is a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio. This fixed molar ratio was found to be synergistic in preclinical studies, and subsequent phase 1 and phase 2 clinical trials demonstrated efficacy, with a particularly strong signal in patients with secondary AML.

Previously reported results from a phase 3 trial revealed improved survival in patients with secondary or high-risk AML treated with CPX-351 compared with 7+3. An exploratory subgroup analysis of the phase 3 study was conducted to compare the outcomes of AML patients treated with CPX-351 or 7+3 who went on to receive allogeneic hematopoietic cell transplant. Out of 309 patients who took part in the trial, 52 patients in the CPX-351 treatment arm and 39 patients in the 7+3 arm received allogeneic hematopoietic cell transplants.

The first 100 days after allogeneic hematopoietic cell transplants represent a critical time. Patients treated with CPX-351 had a lower 100-day mortality rate than patients in the 7+3 group (9.6 percent versus 20.5 percent, respectively). Patients in the CPX-351 group also had a significantly better overall survival than in the 7+3 group. The median overall survival was not yet reached in the CPX-351 arm and was 10.25 months in the 7+3 arm.

Lancet, chair of Moffitt's Department of Malignant Hematology, will present the study results Monday Dec. 5 at 4 p.m. in San Diego Ballroom AB at the Marriott Marquis San Diego Marina.

Explore further: Phase 3 study may be game-changer for acute myeloid leukemia

Related Stories

Phase 3 study may be game-changer for acute myeloid leukemia

April 24, 2014

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

Recommended for you

Dogs detect breast cancer from bandage: researchers

March 24, 2017

Dogs can sniff out cancer from a piece of cloth which had touched the breast of a woman with a tumour, researchers said Friday, announcing the results of an unusual, but promising, diagnostic trial.

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.